Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.,临床等位基因

Patients with the rs12979860 CT genotype and hepatitis C infection may have lower response rates (SVR) to triple therapy (telaprevir, peginterferon alfa-2a/b and ribavirin) as compared to patients with the CC genotype. However, conflicting evidence has been reported. The impact of IL28B genotype may be dampened in patients with prior PegIFN/RBV treatment failure. Other genetic and clinical factors may also influence response to HCV triple therapy.

临床注释ID

1183888969

基因型等位基因

CT

等位基因的功能